Literature DB >> 7897357

Helper virus-free transfer of human immunodeficiency virus type 1 vectors.

J H Richardson1, J F Kaye, L A Child, A M Lever.   

Abstract

Recombinant vectors based on the type 1 human immunodeficiency virus (HIV-1) can be used to deliver genes into cells expressing the HIV receptor, CD4. We have used a transient RNA packaging system to compare the safety and efficacy of HIV-1 vector transduction by wild-type and replication-deficient helper viruses. Helper virus-free vector transfer was consistently achieved when the helper virus gag-pol and env genes were expressed from separate plasmids such that two recombination events were required to form an infectious genome. Other forms of attenuation, such as deletion of the 5' phi region, were inadequate to prevent helper virus transmission. Vector transduction by the wild-type and non-replicating helper viruses occurred with comparable efficiency except in instances where efficient vector RNA expression was dependent upon transactivating factors supplied by the helper virus. These data demonstrate the feasibility of safe gene transfer using HIV-1 vectors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7897357     DOI: 10.1099/0022-1317-76-3-691

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells.

Authors:  P E Mangeot; D Nègre; B Dubois; A J Winter; P Leissner; M Mehtali; D Kaiserlian; F L Cosset; J L Darlix
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Authors:  V N Kim; K Mitrophanous; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

3.  The major human immunodeficiency virus type 2 (HIV-2) packaging signal is present on all HIV-2 RNA species: cotranslational RNA encapsidation and limitation of Gag protein confer specificity.

Authors:  S D Griffin; J F Allen; A M Lever
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 4.  Development of HIV vectors for anti-HIV gene therapy.

Authors:  E Poeschla; P Corbeau; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Identification of a novel splice acceptor in the HIV-1 genome: independent expression of the cytoplasmic tail of the envelope protein.

Authors:  B Berkhout; J L van Wamel
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles.

Authors:  J Reiser; G Harmison; S Kluepfel-Stahl; R O Brady; S Karlsson; M Schubert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

7.  High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells.

Authors:  H Mochizuki; J P Schwartz; K Tanaka; R O Brady; J Reiser
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells.

Authors:  C Fraefel; S Song; F Lim; P Lang; L Yu; Y Wang; P Wild; A I Geller
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Three-dimensional RNA structure of the major HIV-1 packaging signal region.

Authors:  James D Stephenson; Haitao Li; Julia C Kenyon; Martyn Symmons; Dave Klenerman; Andrew M L Lever
Journal:  Structure       Date:  2013-05-16       Impact factor: 5.006

10.  Reconstitution of the myeloid and lymphoid compartments after the transplantation of autologous and genetically modified CD34+ bone marrow cells, following gamma irradiation in cynomolgus macaques.

Authors:  Sonia Derdouch; Wilfried Gay; Didier Nègre; Stéphane Prost; Mikael Le Dantec; Benoît Delache; Gwenaelle Auregan; Thibault Andrieu; Jean-Jacques Leplat; François-Loïc Cosset; Roger Le Grand
Journal:  Retrovirology       Date:  2008-06-19       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.